Skip to main content

Table 1 Patient demographic and medical information

From: The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms

  TP group um-PEA-TP group
Age (mean ± S.D.) 64.1 ± 4.79 64.7 ± 4.12
Gender 5 (M) 20 (F) 9 (M) 21 (F)
Body weight (Kg -mean ± S.D.) 75.3 ± 13.7 77 ± 11.5
Height (cm -mean ± S.D.) 165 ± 5.5 162 ± 7.5
Caucasian (%) 100 100
Comorbidities (%):
diabetes mellitus type II 40 40
hypertension 28 20
ischemic heart disease 20 13.3
dyslipidemia 12 0
morbid obesity 16 20
diverticular disease of the colon 8 3.3
chronic obstructive pulmonary disease 36 33.3
heart rhythm disturbances 4 3.3
osteoporosis 48 43.3
obstructive arterial disease 4 0
chronic venous insufficiency of the lower limbs 4 23.3*
  1. *p < 0.05